AUTHORS
Mackenzie Maberry, MD, Ying Huang, MA, MS2, Sonia Godbole, MD3, Shakthi P. Bhaskar, MD4, Andrew P. Jallouk, MD, PhD5, Ayushi Chauhan, MD6, Swetha Thiruvengadam, MD7, Ajay Major, MD, MBA8, Allison Marie Bock, MD9, Amy A. Ayers10, Steven Bair, MD11, Geoffrey Shouse, DO PhD12, Narendranath Epperla, MD, MS, FACP13, Alex Francisco Herrera, MD14, Alexey V. Danilov, MD, PhD15, Christopher R. Flowers Jr, MD, MS16, Jennifer L. Crombie, MD17, Sairah Ahmed, MD18, Yazeed Sawalha, MD19
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 Vanderbilt University, Nashville, Tennessee, United States
5 Vanderbilt University, Nashville, Tennessee, United States
6 MD Anderson Cancer Center, Houston, Texas, United States
7 City of Hope Cancer Center, Duarte, California, United States
8 University of Colorado School of Medicine, Aurora, Colorado, United States
9 University of Utah, Salt Lake City, Utah, United States
10 MD Anderson Cancer Center, Houston, Texas, United States
11 University of Colorado, Denver, Colorado, United States
12 City of Hope Cancer Center, Duarte, California, United States
13 Hunstman Cancer Institute, Salt Lake City, Utah, United States
14 City of Hope Cancer Center, Duarte, California, United States
15 City of Hope Cancer Center, Duarte, California, United States
16 MD Anderson Cancer Center, Houston, Texas, United States
17 Dana Farber Cancer Institute, Boston, Massachusetts, United States
18 MD Anderson Cancer Center, Houston, Texas, United States
19 The Ohio State University, Columbus, Ohio, United States
ABSTRACT
Background: Relapsed or refractory (R/R) Burkitt lymphoma (BL) carries a dismal prognosis, with long-term survival <20% after salvage chemoimmunotherapy and autologous or allogeneic stem cell transplantation (SCT). Although CAR T-cell therapies achieve complete response (CR) rates of 40–50% (Samples et al., Blood 2025; Van Dorp et al., ASH 2025), data on response durability are limited and conflicting. Further, the typical aggressive and chemorefractory nature of R/R BL necessitates readily available, off-the-shelf options. The CD3xCD20 bispecific antibodies (BsAbs) represent an emerging option; recent reports include a case series of 3 adult patients with R/R BL achieving CR with glofitamab plus polatuzumab (Price et al., NEJM 2025), as well as an interim analysis of the pediatric iMATRIX-GLO trial showing CR in the 3 patients treated with glofitamab plus R-ICE (Minard-Colin et al., ASH 2024). Here, we evaluate real-world outcomes of CD3xCD20 BsAbs in R/R BL.
Methods: This is a multicenter retrospective study of consecutive patients with R/R BL treated with commercial CD3xCD20 BsAbs across 6 US centers within the Collaborative US Bispecific Consortium (CUBIC). Responses were assessed locally per Lugano 2014 criteria. Progression-free survival (PFS) and overall survival (OS) were calculated from treatment initiation.
Results: Ten patients were included. At BsAb initiation, median age was 43 years (range 17-75; 1 patient <18 years), 8 (80%) were male, 2 (20%) Hispanic, and 7 (88%) had performance status of 0-1 (missing 2). Seven patients (88%) had elevated LDH (missing 2), 9 (90%) had stage IV, including 8 (80%) with ≥2 extranodal sites. Two patients had central nervous system (CNS) involvement (1 parenchymal, 1 leptomeningeal). None were HIV positive. Patients received a median of 2 prior lines of therapy (range, 1–3); 2 patients received prior CAR T-cell therapy and 1 prior autologous SCT. None received prior allogeneic SCT. Median time from prior treatment was 1.2 months (range, 0.1–4.0), and 9 (90%) were refractory to their last therapy.
BsAbs were glofitamab (80%, n=8) and epcoritamab (20%, n=2). Two pts (20%) received BsAb monotherapy, while 8 (80%) received combination regimens: 2 with platinum-based chemotherapy (GemOx, GDP) and 6 with polatuzumab (including 2 with radiotherapy and 4 with intrathecal chemotherapy). Rapid step-up dosing was used in 3 patients. Cytokine release syndrome occurred in 3 patients (grade 1, n=2; grade 2, n=1). One patient developed neurotoxicity (grade 3; occurring in the patient with parenchymal CNS involvement).
Median duration of treatment was 1.6 months (range, 0.2-8.9). Eight patients discontinued treatment due to disease progression (n=7) or patient decision (n=1), while 2 remain on treatment (for 7.5 and 8.9 months). The best overall response rate was 50% (5/10), with CR in 40% (4/10; 1 patient treated with glofitamab plus GemOx, and 3 patients treated with glofitamab, polatuzumab, and intrathecal chemotherapy, plus radiation in 1). The median duration of response was 3.6 months (range, 1.8-5.5). CR durations were 2.3, 3.6+ (underwent consolidative allogeneic SCT), 3.7, and 5.5+ months (+ denotes ongoing at last follow-up). The patient with partial response had disease progression 1.9 months after achieving response. Overall, 8 patients (80%) had disease progression; median PFS was 2.1 months (95% CI, 0.4-5.7). Six patients (60%) died; all due to lymphoma progression. The median OS was 7.3 months (95% CI, 0.5 – not reached).
Conclusions: The CD3xCD20 BsAbs, predominantly used in combination regimens, show encouraging preliminary activity in R/R BL, with an ORR of 50% and a CR rate of 40%. However, responses were short-lived, with a median duration of response of 3.6 months and a median PFS of 2.1 months. Although larger studies and longer follow-up are warranted, these findings support the use of BsAbs to induce clinical responses in R/R BL. However, alternative strategies, such as other combinations or consolidative approaches, may be necessary to achieve durable disease control.
DISCLOSURES
Mackenzie Maberry, MD: No relevant conflicts of interest to declare.